- Home
- LIPO vs NDRA Comparison
LIPO vs NDRA Comparison
Compare LIPO & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- NDRA
- Stock Information
- Founded
- LIPO 2005
- NDRA 2007
- Country
- LIPO United States
- NDRA United States
- Employees
- LIPO N/A
- NDRA N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LIPO Health Care
- NDRA Health Care
- Exchange
- LIPO Nasdaq
- NDRA Nasdaq
- Market Cap
- LIPO 3.1M
- NDRA 3.0M
- IPO Year
- LIPO 2022
- NDRA 2017
- Fundamental
- Price
- LIPO $3.14
- NDRA $4.33
- Analyst Decision
- LIPO Strong Buy
- NDRA Strong Buy
- Analyst Count
- LIPO 1
- NDRA 1
- Target Price
- LIPO $16.00
- NDRA $14,000.00
- AVG Volume (30 Days)
- LIPO 6.6M
- NDRA 13.9K
- Earning Date
- LIPO 02-28-2025
- NDRA 03-27-2025
- Dividend Yield
- LIPO N/A
- NDRA N/A
- EPS Growth
- LIPO N/A
- NDRA N/A
- EPS
- LIPO N/A
- NDRA N/A
- Revenue
- LIPO $483,533.00
- NDRA N/A
- Revenue This Year
- LIPO N/A
- NDRA N/A
- Revenue Next Year
- LIPO N/A
- NDRA N/A
- P/E Ratio
- LIPO N/A
- NDRA N/A
- Revenue Growth
- LIPO 0.78
- NDRA N/A
- 52 Week Low
- LIPO $2.21
- NDRA $4.01
- 52 Week High
- LIPO $12.00
- NDRA $2,170.00
- Technical
- Relative Strength Index (RSI)
- LIPO 48.05
- NDRA 35.49
- Support Level
- LIPO $3.35
- NDRA $4.62
- Resistance Level
- LIPO $4.69
- NDRA $5.40
- Average True Range (ATR)
- LIPO 0.62
- NDRA 0.30
- MACD
- LIPO -0.02
- NDRA -0.05
- Stochastic Oscillator
- LIPO 13.31
- NDRA 0.00
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.